Jablonska Jadwiga, Pietrowska Monika, Ludwig Sonja, Lang Stephan, Thakur Basant Kumar
Translational Oncology, Department of Otorhinolaryngology, University Hospital Essen, 45147 Essen, Germany.
Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Institute⁻Oncology Center, Gliwice Branch, 44-100 Gliwice, Poland.
Proteomes. 2019 May 15;7(2):22. doi: 10.3390/proteomes7020022.
Exosomes belong to the group of extracellular vesicles (EVs) that derive from various cell populations and mediate intercellular communication in health and disease. Like hormones or cytokines, exosomes released by cells can play a potent role in the communication between the cell of origin and distant cells in the body to maintain homeostatic or pathological processes, including tumorigenesis. The nucleic acids, and lipid and protein cargo present in the exosomes are involved in a myriad of carcinogenic processes, including cell proliferation, tumor angiogenesis, immunomodulation, and metastasis formation. The ability of exosomal proteins to mediate direct functions by interaction with other cells qualifies them as tumor-specific biomarkers and targeted therapeutic approaches. However, the heterogeneity of plasma-derived exosomes consistent of (a) exosomes derived from all kinds of body cells, including cancer cells and (b) contamination of exosome preparation with other extracellular vesicles, such as apoptotic bodies, makes it challenging to obtain solid proteomics data for downstream clinical application. In this manuscript, we review these challenges beginning with the choice of different isolation methods, through the evaluation of obtained exosomes and limitations in the process of proteome analysis of cancer-derived exosomes to identify novel protein targets with functional impact in the context of translational oncology.
外泌体属于细胞外囊泡(EVs)的范畴,这些囊泡源自各种细胞群体,并在健康和疾病状态下介导细胞间通讯。与激素或细胞因子一样,细胞释放的外泌体在起源细胞与体内远处细胞之间的通讯中发挥着重要作用,以维持稳态或病理过程,包括肿瘤发生。外泌体中存在的核酸、脂质和蛋白质货物参与了无数致癌过程,包括细胞增殖、肿瘤血管生成、免疫调节和转移形成。外泌体蛋白质通过与其他细胞相互作用介导直接功能的能力使其有资格成为肿瘤特异性生物标志物和靶向治疗方法。然而,血浆来源的外泌体具有异质性,包括(a)源自各种体细胞(包括癌细胞)的外泌体,以及(b)外泌体制备过程中被其他细胞外囊泡(如凋亡小体)污染,这使得获取用于下游临床应用的可靠蛋白质组学数据具有挑战性。在本手稿中,我们回顾了这些挑战,从不同分离方法的选择开始,到对获得的外泌体的评估,以及癌症来源外泌体蛋白质组分析过程中的局限性,以确定在转化肿瘤学背景下具有功能影响的新型蛋白质靶点。